ReviewMicrobes and infection2010
The immunoregulatory properties of oncolytic myxoma virus and their implications in therapeutics.
Review in Microbes and infection, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 34 citations in OpenAlex.
- Review
- Article
- Prospects for the use of viral proteins for the construction of chimeric toxins.Archives of virology · 2024Review
- Cowpox Viruses: A Zoo Full of Viral Diversity and Lurking Threats.Biomolecules · 2023Review
- Progress on Poxvirus E3 Ubiquitin Ligases and Adaptor Proteins.Frontiers in immunology · 2021Review
- Myxoma Virus-Loaded Mesenchymal Stem Cells in Experimental Oncolytic Therapy of Murine Pulmonary Melanoma.Molecular therapy oncolytics · 2020Article
- Review
- Oncolytic Virotherapy with Myxoma Virus.Journal of clinical medicine · 2020Review
- Poxviruses as Gene Therapy Vectors: Generating Poxviral Vectors Expressing Therapeutic Transgenes.Methods in molecular biology (Clifton, N.J.) · 2019Article
- Identification of host DEAD-box RNA helicases that regulate cellular tropism of oncolytic Myxoma virus in human cancer cells.Scientific reports · 2017Article
- Myxoma Virus dsRNA Binding Protein M029 Inhibits the Type I IFN-Induced Antiviral State in a Highly Species-Specific Fashion.Viruses · 2017Article
- An overview of the lagomorph immune system and its genetic diversity.Immunogenetics · 2016Review
- Gene delivery of a viral anti-inflammatory protein to combat ocular inflammation.Human gene therapy · 2015Article
- Oncolytic Poxviruses.Annual review of virology · 2014Article
- Targeting gallbladder cancer: oncolytic virotherapy with myxoma virus is enhanced by rapamycin in vitro and further improved by hyaluronan in vivo.Molecular cancer · 2014Article
- Evolution of viral sensing RIG-I-like receptor genes in Leporidae genera Oryctolagus, Sylvilagus, and Lepus.Immunogenetics · 2014Article
- Oncolytic myxoma virus: the path to clinic.Vaccine · 2013Review
- Review
- Myxoma and vaccinia viruses bind differentially to human leukocytes.Journal of virology · 2013Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Myxoma virus (MYXV) is a poxvirus with a strict rabbit-specific host-tropism for pathogenesis. The immunoregulatory factors encoded by MYXV can suppress some functions of immune effectors from other species. We review their mechanisms of action, implications in therapeutics and the potential to improve MYXV as an oncolytic agent in humans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.